Kornimate/medical-research-clean huggingface dataset:
effects of increased cf-lvad pump speed during sustained submaximal exercise

Conditions: Heart Failure

Summary: this randomized trial has been designed to study if it is possible to enhance work capacity during submaximal efforts in heart failure patients supported with continuous-flow left ventricular assist devices (cf-lvad). the hypothesis is that exercise tolerability during low to moderate workloads in cf-lvad patients can be increased when pump speed is increased soon after the onset of exercise.

to test the hypothesis described above the investigators will study submaximal exercise tests below anaerobic threshold in patients supported with cf-lvads.each patient will perform two tests- one with baseline cf-lvad pump speed and the other with incrementally increased pump speed.

Eligibility criteria:
inclusion criteria: * ischemic and non-ischemic cardiomyopathy patients with cf-lvads,signed informed consent. exclusion criteria: * unstable patients, cf-lvad implantation less than three months ago.

Keywords: heart-assist devices exercise capacity
effectiveness, safety, and economic evaluation of goserelin microspheres for injection and goserelin sustained-release implants in prostate cancer patients: a real-world study

Conditions: Prostate Cancers

Summary: prostate cancer (pc) is the most common malignancy in the male genitourinary system. in china, both the incidence and mortality rates of pc have shown a significant upward trend in recent years. chinese patients are typically diagnosed at older ages with higher preoperative prostate-specific antigen (psa) levels compared to western populations, indicating a more aggressive disease phenotype. this may explain the lower 5-year survival rates in chinese pc patients. over the past three decades, the age-standardized incidence of pc in china has surged by 95.2%, while the global rate increased by only 13.2%. conversely, global pc mortality decreased by 15.7%, whereas china saw a mere 5.3% reduction. the high economic burden on patients and healthcare systems underscores the urgency of optimizing treatment strategies. direct annual medical costs for pc in china average $3,500 per patient, with drug expenses accounting for over 60% and out-of-pocket payments comprising approximately 20%. these costs far exceed those of other malignancies, posing sustainability challenges for families and insurance systems. androgen deprivation therapy (adt), including surgical or chemical castration, remains the cornerstone for advanced pc. chemical castration via luteinizing hormone-releasing hormone (lhrh) agonists or antagonists offers comparable survival benefits to surgical castration but with improved quality of life. goserelin, a synthetic gnrh analog, has been widely used since 1987. current formulations include a sustained-release implant (10.8 mg/3.6 mg) administered subcutaneously every 28 days using a 16g needle (outer diameter: 1.6 mm), which may cause injection-site injuries, and a newer microsphere formulation (3.6 mg) delivered intramuscularly via a 21g needle (outer diameter: 0.8 mm), enhancing patient tolerance. while phase iii trials showed no significant efficacy differences between the two formulations, real-world evidence is lacking. this retrospective cohort study aims to evaluate the effectiveness, safety, and cost-effectiveness of both formulations using real-world data.


Eligibility criteria:
inclusion criteria: - 1. patients with histologically confirmed prostate cancer (pc) deemed suitable for endocrine therapy (excluding neoadjuvant endocrine therapy). 2. at least 18 years old 3. prescribed 3.6 mg goserelin every 4 weeks as monotherapy or in combination with anti-androgen therapy. exclusion criteria: * 1. hypersensitivity to lhrh, its analogs, or any component of goserelin. 2. previous or concurrent hormone therapy, except for conventional anti-androgen therapy administered within 2 weeks before goserelin treatment. 3. diagnosis or suspicion of hormone-resistant pc, history of hypophysectomy, adrenalectomy, or pituitary lesions. 4.scheduled for radical radiotherapy (adjuvant radiotherapy post-radical prostatectomy \[rp\] combined with goserelin is permitted) or planned neoadjuvant hormone therapy prior to rp.
effects of core stabilization exercises with and without dry cupping in patients with sacroiliac joint dysfunction

Conditions: Sacroiliac Joint Dysfunction

Summary: the aim of this study is to compare the effects of core stabilization exercises with and without dry cupping on pain and disability in patients with sacroiliac joint dysfunction.

low back pain (lbp) is recognized by its most common symptom - pain - and is known as the primary cause of disability one of the most frequent pain-producing factors in patients with lbp is sacroiliac joint dysfunctions (sjd). the sacroiliac joint dysfunction syndrome (sijds) is a contentious topic that is a common cause of low back pain (lbp) and patients often seek physical therapy helps to deal with their symptoms. dry cupping on the sij is a physical therapy technique that has been supported by research in numerous areas, including pain reduction and sij mobility promotion. but, in previous studies, there is very less literature regarding determining effects of the dry cupping on sacroiliac joint dysfunction. therefore there is a dire need to explore the effect of dry cupping on sacroiliac joint dysfunction. this study aims the management of pain disability and functional impairment in persons with sacroiliac joint dysfunction particularly core stabilization exercises along with dry cupping therapy.

Eligibility criteria:
inclusion criteria: * chronic low back pain for more than 3 months * pain on performing pain provocative tests for sacroiliac dysfunction * oswestry disability index above 20% but below 80% exclusion criteria: * participants suffering from specific low back pain like pivd with instability or any radicular symptoms, lumbar spondylosis, lumbarcanal stenosis, spondylolisthesis, sensory deficits, malignancies and tuberculosis. * any traumatic conditions around the pelvis and lower limbs, any infectious, tumors conditions around the pelvis. * pregnancy, any lower limb abnormalities, any recently underwent abdominal and low back surgery.

Keywords: dry cupping core stabilization exercise sacroiliac joint dysfunction
treatment options for chronic urticaria

Conditions: Chronic Urticaria

Summary: chronic urticaria is one of the most common dermatological disease affecting many people, exploring most treatment options for its treatment is need of an hour. our study aim to compare the efficacy of autologous serum therapy (ast) with levocetirizine in chronic urticaria patients

urticaria is one of the most common skin diseases causing redness, and swelling in the dermis and epidermal layers and are severely pruritic. chronic urticaria is further sub-divided into chronic spontaneous urticaria and chronic inducible urticaria. international guidelines recommend non-sedating antihistamines once daily as first-line therapy for chronic spontaneous urticaria and chronic inducible urticaria. levocetirizine which is classified as a second-generation antihistamine and works by blocking histamine h1-receptors , is an effective treatment for ciu, characterized not only by a rapid and sustained response, but also by an important improvement in qol. autologous serum therapy (ast) has been tried by many in patients with cau with variable results, majority showing beneficial effects. ast has also been used in the treatment of ocular alkali burn patients presence of tolerance generating anti-idiotype antibodies to mast cell degranulating antigens that induce remission of the disease forms the basis of ast and this therapy has been tried in various autoimmune diseases our study aim to compare the efficacy of autologous serum therapy (ast) with levocetirizine in chronic urticaria patients objective "to compare the efficacy of autologous serum therapy vs levocetrizine in the treatment of chronic urticaria in tertiary care hospital" data collection: data will be collected on prescribed proforma which is attached, at dermatology opd, sheikh zayed hospital, rahim yar khan. patient will be selected on basis of inclusion \& exclusion criteria. informed consent will be taken from selected patients before data collection. study will include 72 patients which will be divided into 2 groups, a \& b, 36 in each group. group a will receive ast, group b will receive oral levocetirizine 5mg 1 tablet hs. 5 ml of blood will be collected and centrifuged at 3000 rpm for 10 min to obtain serum,2 ml of the serum will be injected into the gluteus muscle. we will give the patients 9 injections of autologous serum intramuscularly once a week . follow up visit will be after 2 months of last session. data analysis: data will be analyzed by spss v25.0

Eligibility criteria:
inclusion criteria: * age: 13-60 years * gender: both male and female * patients having urticaria for more than 6 weeks diagnosed clinically exclusion criteria: * pregnancy and lactating females * patients who are immunosuppressed either due to medication or disease. * patients suffering from chronic diseases i-e chronic liver disease, chronic kidney disease. * patients taking steroids in last 2 weeks.

Keywords: chronic urticaria autologous serum therapy levocetrizine
high dose of dual therapy plus bismuth for helicobacter pylori treatment

Conditions: Helicobacter Pylori Infection

Summary: dual therapy for helicobacter pylori including a proton pump inhibitor (ppi) and amoxicillin. amoxicillin has low resistance rate as well as low percentage of side effects. no trial has examined the the efficacy of high dose of dual therapy plus bismuth for h. pylori treatment.this study is designed to evaluate the efficacy and safety of the addition of bismuth to high dose of dual therapy for h. pylori eradication.


Eligibility criteria:
inclusion criteria: * participants with non-ulcer functional dyspepsia or peptic ulcer disease * ability and willingness to participate in the study and to sign and give informed consent * confirmed h. pylori infection exclusion criteria: * less than 18 years old * with previous gastric surgery * major systemic diseases * pregnancy or lactation * allergy to any of the study drugs administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion

Keywords: helicobacter pylori therapy
ykl-40 and complications in type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: in this study, the investigators plan to establish the relationship between plasma concentration of ykl-40 with various vascular complications in the patients of type 2 diabetes.

it is well recognized now that diabetes mellitus is a systemic vasculopathy and causes various micro- and macrovascular complications. vascular damage and endothelium dysfunction in diabetes mellitus involve a chronic inflammatory process via a complicated mechanism. ykl-40 is a 40 kd lectin molecule. it is secreted by various cells, including macrophages, vascular smooth muscle cells and giant cells, and the level of ykl-40 is found elevated in both acute (eg. infection) and chronic (eg. rheumatoid arthritis, systemic lupus erythematosus or cirrhosis of the liver) inflammatory processes. the plasma concentration of ykl-40 is elevated in the patients of type 2 diabetes mellitus compared with non-diabetic controls, and is associated with insulin resistance, fasting plasma glucose and plasma il-6 concentrations. furthermore, the concentration of ykl-40 is elevated and is associated with the severity of albuminuria in the patients of type 1 diabetes. the objective of this study is to establish the relationship between plasma concentration of ykl-40 with various vascular complications in the patients of type 2 diabetes, and to evaluate its potential as a biomarker for the vascular diabetic complications in patients with type 2 diabetes.

Eligibility criteria:
inclusion criteria: * clear consciousness * type 2 diabetic patient

Keywords: type 2 diabetes mellitus diabetic complications ykl-40
helping men have healthy babies

Conditions: HIV/AIDS; HIV Prevention

Summary: many men living with hiv (mlwh) want to have children. hiv-rna suppression can minimize sexual hiv transmission risks while allowing for conception. the study will evaluate a safer conception intervention that leverages men's motivations to have healthy babies in order to promote serostatus disclosure and early art initiation. the intervention is based on the investigators' safer conception conceptual framework, which considers individual, dyadic, and structural factors that affect periconception risk behavior.

the study will evaluate and test a safer conception intervention that leverages men's motivations to have healthy babies in order to promote serostatus disclosure and early art initiation. the intervention is based on a safer conception conceptual framework, which considers individual, dyadic, and structural factors that affect periconception risk behavior. the researchers will conduct an open pilot to refine the intervention. the study will enroll men who want to have children with uninfected or unknown status female partners. men will participate in three study sessions offering motivational interviewing and problem solving to help men develop a plan to have a healthy baby. the counseling will explore safer conception options including safe disclosure, delaying conception attempts until on art with viral suppression, sti testing and treatment, timing condomless sex to peak fertility. the primary outcome is hiv rna suppression at 12 weeks. secondary outcomes include acceptability, feasibility, early art uptake, adherence, serostatus disclosure, couples hiv counseling and testing uptake, and limiting unprotected sex to peak fertility.

Eligibility criteria:
inclusion criteria: * identifies as male * not on art, or initiated art within the past 3 months * hiv-positive and status known for at least 1 (one) month, * in care/patient at ithembalabantu clinic * want to have a child in the next year, * with a stable sexual pregnancy partner for at least 6 months, * their pregnancy partner should be hiv-uninfected or hiv-status unknown, * their pregnancy partner should not be known to be currently pregnant, * have their own/ a mobile phone * be fluent in either english or isizulu and, * able to participate in informed consent process * not sterilized or known to be infertile
nurse empathic behaviour to reduce the fear in patients of preoperative cardiac surgery

Conditions: Cardiovascular Disease

Summary: the objective was to compare the frequency and intensity of symptoms of fear in patients of preoperative cardiac surgery who received empathic behaviour from nurse or those who received no specific type of empathic behaviour. this is a randomized clinical trial. the sample consisted of 44 patients in preoperative of cardiac surgery, who were divided in two groups: empathic behaviour by nurses and without specific empathic behaviour. fear was assessed at two time points: before and after the intervention. the instrument used was developed and validated, comprising 15 defining characteristics of the nursing diagnosis fear. the hypothesis is that the group who received empathic behaviour from nurse will reduce the anxiety.

primary outcome is fear. fear was assessed by a nurse using of an instrument developed and validated previous, based on 15 defining characteristics described by north american nursing diagnosis association for the nursing diagnosis fear: apprehension, increased tension, exciting, nervousness, verbalization of fear (expressed concern), increased pulse, nausea, vomiting, fatigue, abnormal respiratory rate, increased perspiration, dry mouth, fear of death (reported), crying and impaired bowel motility. patients were evaluated for the presence and absence of these fear symptoms through scores: 0 (no symptom) and 1 (presence of symptom). for analysis of the results was carried out the sum of the scores of each symptom, ranging from 0 to 15, with the higher the score, the greater was the fear symptoms presented by the patient.

Eligibility criteria:
inclusion criteria: * patients older than 18 years * patient who agreed to participate in the study by signing the consent form at least 24 hours prior to surgery exclusion criteria: * patients in preoperative cardiac transplantation * patients who did not have at least two defining characteristics of the nursing diagnosis fear * patients using anxiolytics * smokers and / or patients who drank any amount of alcohol daily

Keywords: fear; thoracic surgery; nursing care; preoperative care
effects of topical gentamicin on the prevention of peritoneal dialysis related infection

Conditions: Peritoneal Dialysis-related Infection

Summary: peritoneal dialysis-related infection is a complication that leads to peritoneal dialysis catheter removal or patient death. the present study aimed to investigate peritoneal dialysis-related infection, causative pathogens resulting in topical 2% mupirocin ointments period compare with 0.1% gentamicin cream period. rate of catheter removal, time to first peritoneal dialysis-related infection after apply gentamicin cream.


Eligibility criteria:
inclusion criteria: * age greater than or equal to 20 years * end stage renal disease patients on peritoneal dialysis follow up at phramongkutklao hospital's peritoneal dialysis clinic between january 1, 2021 to march 31, 2023 * start peritoneal dialysis or follow up at phramongkutklao hospital's peritoneal dialysis clinic at least 90 days before recruited * use topical mupirocin ointment for prevention of peritoneal dialysis-related infection between january 1, 2021 to december 31, 2021 * can be used line application throughout the study exclusion criteria: * allergy to gentamicin or components * previous systemic antibiotics use within 90 days before recruited * previous peritoneal dialysis-related infection within 28 days before recruited * immunosuppressants used * prospective follow up less than 2 months * don't sign informed consent

Keywords: peritoneal dialysis-related infection infectious peritonitis exit-site infection infection rate drug susceptibility
prospective assessment of cost-effectiveness and side-effects of depressive patients treated with ect or tca

Conditions: Depressive Disorder, Major

Summary: prospective observational cohort study to determine cost-effectiveness of ect compared to medication in the treatment of major depressive disorder (mdd) in the netherlands.

rationale: currently, detailed information on the cost-effectiveness of ect based on real-world data is lacking, as well as the comparative cost-effectiveness with respect to medication. reliable information on outcomes of ect in comparison with antidepressant treatment and its cognitive side-effects is needed for patients and clinicians to make a balanced and shared decision regarding choosing or refraining from ect. objective: primary objective: determine (cost)-effectiveness of ect compared to medication by determining the impact of treatment for mdd with ect or tca on remission rates using a one-year time horizon (trial-based economic evaluation) secondary objective: determine side-effects of ect compared to medication by determining the impact of treatment with ect or medication on side-effects and quality of life during a one-year follow-up study design: observational, parallel inception cohort study of patients who will undergo standard clinical care according to current guidelines. study population: 110 patients (\>18 yrs.) with a depressive episode (unipolar mdd) who will start ect (ect group) and 110 patients (\>18 yrs.) with a depressive episode (unipolar mdd) who will undergo treatment with antidepressants will be recruited from specialized clinics (academic hospital, general hospital and ggz-institute) and followed-up for one year to gather reliable data on efficacy including relapse rates, cost-effectiveness, quality of life and cognitive functioning.

Eligibility criteria:
inclusion criteria: * adult patients (\>18 years) with a major depressive disorder who will either start with ect or medication * failed response to at least 1 adequate dose-duration trial with antidepressants * moderate or severe depression (hdrs-17 \>16) exclusion criteria: * lifetime diagnosis schizophrenia or schizoaffective disorder, current substance abuse disorder, organic brain syndrome * the presence of a concurrent significant medical condition impeding the ability to participate

Keywords: depressive disorder ect electroconvulsive therapy antidepressants cost-effectiveness
impact of walking aids on the occurrence of carpal tunnel syndrome in rehabilitation

Conditions: Carpal Tunnel Syndrome

Summary: the purpose of this study is to assess the impact of the use of technical walking aids in the adult population undergoing rehabilitation by evaluating clinical, electrophysiological, and iconographic parameters before and after the use of these devices.

the current evidence indicates that the short-term use of walking aids elicits pressure-induced anatomical changes of the median nerve and that long-term use of walking aids leads to a significant percentage of stroke patients developing clinical symptoms of carpal tunnel syndrome. we will investigate the consequences of using technical walking aids for gait in a broader population of rehabilitation patients. the rehabilitation setting per se may be considered a useful clinical 'human pathological model' for peripheral nerve entrapment. recruited patients will be naïve to previous use of walking aids and de novo will start using them for gait rehabilitation, regardless of the underlying disease. this intervention model will allow us to identify clinical, electrophysiological, and anatomical changes of the median nerve due to the daily direct pressure elicited by walking aids. we consider that a one-month duration of use of walking aids is needed to observe detectable changes in electrophysiological and ultrasonographical assessment to elicit entrapment neuropathies in patients prone to developing them.

Eligibility criteria:
inclusion criteria: * admitted into an in-patient rehabilitation unit * functional ambulation category ≥ 1 * de novo need for a walking aid * at least one functional upper limb * expected duration of need for walking aid at least one month exclusion criteria: * less than 18 years old * current use of walking aid or use of a walking aid less than 6 months ago) * difficulty filling out questionnaires or understanding instructions in french * medical contraindications to the use of walking aids * refusal to sign the consent form.

Keywords: carpal tunnel